| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Fennec Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.60 |
| 52 Week High | US$11.92 |
| 52 Week Low | US$5.00 |
| Beta | 0.29 |
| 11 Month Change | -12.36% |
| 3 Month Change | -22.11% |
| 1 Year Change | -27.93% |
| 33 Year Change | -27.46% |
| 5 Year Change | 31.76% |
| Change since IPO | -95.06% |
Recent News & Updates
Recent updates
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be
Aug 15
Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?
Jul 16Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop
Jun 02Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 18Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates
Nov 09Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children
Sep 20Buying Fennec Pharma Ahead Of September PDUFA For Pedmark
Aug 23Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor
Aug 01Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?
Oct 29Fennec Could See Upside If Pedmark Gets Approved
Jul 29Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow
Jun 18Fennec Pharma resubmits PEDMARK application in U.S.
May 28Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans
May 26Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 01Do Institutions Own Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares?
Mar 02Have Insiders Been Selling Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares This Year?
Jan 26Companies Like Fennec Pharmaceuticals (NASDAQ:FENC) Are In A Position To Invest In Growth
Dec 22Fennec Pharmaceuticals EPS misses by $0.05
Nov 16Fennec Pharmaceuticals: The Compensation Is What's Missing
Nov 05Shareholder Returns
| FENC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.3% | 3.5% | 3.1% |
| 1Y | -27.9% | 14.9% | 25.4% |
Return vs Industry: FENC underperformed the US Biotechs industry which returned 15.7% over the past year.
Return vs Market: FENC underperformed the US Market which returned 25.6% over the past year.
Price Volatility
| FENC volatility | |
|---|---|
| FENC Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: FENC's share price has been volatile over the past 3 months.
Volatility Over Time: FENC's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 29 | Rosty Raykov | www.fennecpharma.com |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Fennec Pharmaceuticals Inc. Fundamentals Summary
| FENC fundamental statistics | |
|---|---|
| Market cap | US$156.52m |
| Earnings (TTM) | US$2.74m |
| Revenue (TTM) | US$48.89m |
56.0x
P/E Ratio3.1x
P/S RatioIs FENC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FENC income statement (TTM) | |
|---|---|
| Revenue | US$48.89m |
| Cost of Revenue | US$2.17m |
| Gross Profit | US$46.72m |
| Other Expenses | US$43.98m |
| Earnings | US$2.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 95.55% |
| Net Profit Margin | 5.59% |
| Debt/Equity Ratio | -2,341.6% |
How did FENC perform over the long term?
See historical performance and comparison